INFO & CONTACTS:  +39 02 2390 1

A Phase 3, Multi-Center, Randomized, Open-Label Clinical Study of Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Phase: Phase III clinical trials

Principal Investigator: Dott. Pietrantonio Filippo

Main Facility: Oncologia Medica Gastroenterologica

Drug: Tislelizumab

Pathologies:

ClinicalTrials.gov: Read the details about clinical trials

This is a randomized, open-label, Phase 3 study designed to demonstrate the noninferiority of drug exposure following treatment with tislelizumab administered as SC injection versus IV infusion as 1L therapy for locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma. The study is composed of a screening period, a treatment period, and a follow-up period.

Eligible patients will be randomized in a 2:1 ratio to receive either

  • Tislelizumab 300 mg SC injection Q3W + chemotherapy (Arm A) or
  • Tislelizumab 200 mg IV infusion Q3W + chemotherapy (Arm B).

The enrolled patients will be stratified based on the following

factors at randomization:

o PD-L1 expression (≥ 5% versus < 5%)

o Presence of peritoneal metastasis (yes or no)

o Investigator’s choice of chemotherapy (oxaliplatin + 5-FU +

leucovorin versus oxaliplatin + capecitabine versus cisplatin + 5-FU).

Tislelizumab given in combination with chemotherapy is well tolerated and the safety profile is consistent with that of other PD-1 inhibitors given in combination with chemotherapy.

SC delivery of biotherapeutics has become a valuable alternative to IV administration across many disease areas. SC administration has been proven to be effective, safe, well tolerated, generally preferred by patients and healthcare providers, and to result in reduced drug delivery-related healthcare costs and resource use.

Last update: 14/07/2026

Subscribe to the newsletter

Sign up for our newsletter to stay informed about news, events, and updates from the Institute

Subscribe